Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Metadata
Title
Multiple factors other than p53 influence colon cancer sensitivity to paclitaxel
Authors
Neeraj Sharma
Satya Ramachandran
Mark Bowers
Manni Yegappan
Ronald Brown
Shewan Aziz
Robert Chapman
Bennett W. Yu
Publication date
01-10-2000
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2000
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800000155

Other articles of this Issue 4/2000

Cancer Chemotherapy and Pharmacology 4/2000 Go to the issue

ORIGINAL ARTICLE

Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents

CLINICAL TRIAL REPORT

A phase I study of prolonged ambulatory infusion carboplatin with oral etoposide showing activity in prostate cancer

ORIGINAL ARTICLE

Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia

ORIGINAL ARTICLE

Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines

ORIGINAL ARTICLE

A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion

ORIGINAL ARTICLE

In vitro evaluation of newly developed chalcone analogues in human cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits